



Toxicological Profile for Chlorodibenzofurans (CDFs)

April 2023



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Robin M. Ikeda, M.D., M.P.H.

Acting Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.

Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
April 2023	Final toxicological profile released
January 2022	Draft for public comment toxicological profile released
May 1994	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Hana R. Pohl, M.D., Ph.D. (Lead)
Breanna Alman, M.P.H.
Franco Scinicariello, M.D., M.P.H.

Lisa Ingerman, Ph.D., D.A.B.T.
Jessica Myers, Ph.D.
Mario Citra, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Center for Public Health and Environmental Assessment; EPA, Office of Water.

PEER REVIEWERS

1. Michael D. Collins, Ph.D., M.S.P.H., M.S., Professor; UCLA Fielding School of Public Health; Los Angeles, California
2. Charles J. Everett, Ph.D.; U.S. Department of Veterans Affairs; Ralph H. Johnson VA Medical Center; Charleston, South Carolina
3. Eric J. Reiner; University of Toronto; Toronto, Ontario, Canada

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs).....	9
CHAPTER 2. HEALTH EFFECTS.....	16
2.1 INTRODUCTION.....	16
2.2 DEATH	52
2.3 BODY WEIGHT.....	53
2.4 RESPIRATORY	56
2.5 CARDIOVASCULAR.....	57
2.6 GASTROINTESTINAL.....	59
2.7 HEMATOLOGICAL	61
2.8 MUSCULOSKELETAL	62
2.9 HEPATIC.....	63
2.10 RENAL	67
2.11 DERMAL.....	68
2.12 OCULAR	70
2.13 ENDOCRINE.....	71
2.14 IMMUNOLOGICAL	74
2.15 NEUROLOGICAL.....	79
2.16 REPRODUCTIVE	80
2.17 DEVELOPMENTAL.....	87
2.18 OTHER NONCANCER.....	115
2.19 CANCER.....	117
2.20 MECHANISM OF ACTION	122
2.21 GENOTOXICITY	125
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	127
3.1 TOXICOKINETICS.....	127
3.1.1 Absorption.....	127
3.1.2 Distribution	130
3.1.3 Metabolism.....	136
3.1.4 Excretion	138
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	143
3.1.6 Animal-to-Human Extrapolations	145
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE... 145	145
3.3 BIOMARKERS OF EXPOSURE AND EFFECT.....	146

3.3.1	Biomarkers of Exposure.....	147
3.3.2	Biomarkers of Effect.....	148
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	149
CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION.....	151
4.1	CHEMICAL IDENTITY.....	151
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	151
CHAPTER 5.	POTENTIAL FOR HUMAN EXPOSURE.....	159
5.1	OVERVIEW.....	159
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	162
5.2.1	Production.....	162
5.2.2	Import/Export.....	165
5.2.3	Use.....	165
5.2.4	Disposal.....	165
5.3	RELEASES TO THE ENVIRONMENT.....	167
5.3.1	Air.....	176
5.3.2	Water.....	176
5.3.3	Soil.....	177
5.4	ENVIRONMENTAL FATE.....	178
5.4.1	Transport and Partitioning.....	178
5.4.2	Transformation and Degradation.....	183
5.5	LEVELS IN THE ENVIRONMENT.....	185
5.5.1	Air.....	188
5.5.2	Water.....	196
5.5.3	Sediment and Soil.....	200
5.5.4	Other Media.....	202
5.6	GENERAL POPULATION EXPOSURE.....	211
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	224
CHAPTER 6.	ADEQUACY OF THE DATABASE.....	227
6.1	INFORMATION ON HEALTH EFFECTS.....	227
6.2	IDENTIFICATION OF DATA NEEDS.....	229
6.3	ONGOING STUDIES.....	236
CHAPTER 7.	REGULATIONS AND GUIDELINES.....	237
CHAPTER 8.	REFERENCES.....	239
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR CDFS.....	B-1
APPENDIX C.	USER'S GUIDE.....	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	D-1
APPENDIX E.	GLOSSARY.....	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	F-1

LIST OF FIGURES

1-1. Basic Chemical Structure of Chlorodibenzofurans (CDFs), Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs), and Polychlorinated Biphenyls (PCBs).....	2
1-2. Health Effects Found in Animals Following Oral Exposure to 2,3,7,8-Tetrachlorodibenzofuran.....	4
1-3. Health Effects Found in Animals Following Oral Exposure to 1,2,3,7,8-Pentachlorodibenzofuran.....	5
1-4. Health Effects Found in Animals Following Oral Exposure to 2,3,4,7,8-Pentachlorodibenzofuran.....	6
1-5. Health Effects Found in Animals Following Oral Exposure to 1,2,3,6,7,8-Hexachlorodibenzofuran.....	7
1-6. Summary of Sensitive Targets of 1,2,3,7,8-Pentachlorodibenzofuran – Oral.....	10
1-7. Summary of Sensitive Targets of 2,3,4,7,8-Pentachlorodibenzofuran – Oral.....	11
1-8. Summary of Sensitive Targets of 1,2,3,6,7,8-Hexachlorodibenzofuran – Oral.....	12
2-1. Overview of the Number of Studies Examining Chlorodibenzofurans (CDFs) Health Effects.....	23
2-2. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Oral.....	42
5-1. Number of NPL Sites with Chlorodibenzofuran (CDF) Contamination.....	159
6-1. Summary of Existing Health Effects Studies on Chlorodibenzofurans (CDFs) by Route and Endpoint.....	228

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,2,3,7,8-Pentachlorodibenzofuran.....	13
1-2. Minimal Risk Levels (MRLs) for 2,3,4,7,8-Pentachlorodibenzofuran.....	14
1-3. Minimal Risk Levels (MRLs) for 1,2,3,6,7,8-Hexachlorodibenzofuran	15
2-1. Summary of World Health Organization (WHO) 1998 and 2005 Toxicity Equivalency Factors (TEFs).....	19
2-2. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Oral.....	24
2-3. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Dermal	50
2-4. Results of Epidemiological Studies Evaluating Exposure to CDFs and Body Weight Effects.....	54
2-5. Results of Epidemiological Studies Evaluating Exposure to CDFs and Cardiovascular Effects.....	58
2-6. Results of Epidemiological Studies Evaluating Exposure to CDFs and Dermal Effects	69
2-7. Results of Epidemiological Studies Evaluating Exposure to CDFs and Reproductive Effects.....	81
2-8. Results of Epidemiological Studies Evaluating Exposure to CDFs and Developmental Effects.....	87
2-9. Results of Epidemiological Studies Evaluating Exposure to CDFs and Other Noncancer Effects.....	115
2-10. Results of Epidemiological Studies Evaluating Exposure to CDFs and Cancer Effects.....	118
2-11. Genotoxicity of Chlorodibenzofurans (CDFs) <i>In Vitro</i>	125
3-1. Half-Times of Various CDF Congeners in Hepatic and Adipose Tissues of Marmoset Monkeys Subcutaneously Administered a Single Dose of a CDD/CDF Mixture	132
3-2. Estimated Blood Elimination Half-Lives for Chlorodibenzofuran (CDF) Congeners in Humans...	139
4-1. Chemical Identity of Chlorodibenzofurans (CDFs).....	152
4-2. Physical and Chemical Properties of Chlorodibenzofurans (CDFs)	154
5-1. Facilities that Produce, Process, or Use Dioxin and Dioxin-like Compounds	162
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Dioxin and Dioxin-like Compounds	168
5-3. Levels of Chlorodibenzofurans (CDFs) in Commercial Chlorinated Phenols ($\mu\text{g/g}$)	173
5-4. Levels of Chlorodibenzofurans (CDFs) in Commercial Polychlorinated Biphenyls (PCBs) ($\mu\text{g/g}$)	174

5-5. Estimated BCFs and BAFs for Chlorodibenzofurans (CDFs) in Aquatic Organisms.....	181
5-6. Lowest Limit of Detection Based on Standards	185
5-7. Summary of Environmental Levels of Chlorodibenzofurans (CDFs).....	186
5-8. Chlorodibenzofuran (CDF) Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	186
5-9. Congener-specific Monitoring Data from the NDAMN 1998–2004.....	189
5-10. Concentrations of Chlorodibenzofurans (CDFs) in Ambient Indoor and Outdoor Air in North America and Oceans.....	191
5-11. Porewater Concentrations of Chlorodibenzofurans (CDFs) (pg/L) at Four Locations of the Lower Passaic River Obtained During Four Sampling Periods	198
5-12. Levels of Chlorodibenzofurans (CDFs) in Fish and Other Aquatic Organisms.....	203
5-13. Chlorodibenzofuran (CDF) Levels (pg/g Lipid) in the U.S. Population 1999–2004	212
5-14. Chlorodibenzofuran (CDF) Levels (pg/g Lipid) in the U.S. Population 2005–2010	213
5-15. Levels of Chlorodibenzofurans (CDFs) in Human Adipose Tissue	222
5-16. Levels of Chlorodibenzofurans (CDFs) in Human Milk.....	223
5-17. Mean Levels of Chlorodibenzofurans (CDFs) in Human Whole Blood (ppt Lipid) from Various Countries.....	224
7-1. Regulations and Guidelines Applicable to Chlorodibenzofurans (CDFs).....	237